Boston Trust Walden Corp lessened its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 4.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,035,813 shares of the biopharmaceutical company's stock after selling 47,249 shares during the period. Halozyme Therapeutics accounts for approximately 0.9% of Boston Trust Walden Corp's investment portfolio, making the stock its 17th biggest position. Boston Trust Walden Corp owned approximately 0.91% of Halozyme Therapeutics worth $114,354,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Hilton Head Capital Partners LLC acquired a new stake in Halozyme Therapeutics in the 3rd quarter worth about $33,000. CoreCap Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 98.0% during the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 150 shares during the last quarter. MidFirst Bank acquired a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $28,000. Finally, Quantbot Technologies LP purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $30,000. 97.79% of the stock is owned by hedge funds and other institutional investors.
Halozyme Therapeutics Stock Up 1.3%
HALO stock opened at $130.34 on Thursday. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $134.00. The firm has a market cap of $14.79 billion, a PE ratio of 26.09, a PEG ratio of 0.48 and a beta of 0.92. The firm's 50 day moving average price is $114.94 and its 200-day moving average price is $84.31. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to analysts' expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The firm's quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.54 earnings per share. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.32 EPS for the current year.
Analyst Ratings Changes
A number of analysts have recently issued reports on HALO shares. JPMorgan Chase & Co. lifted their price target on Halozyme Therapeutics from $78.00 to $79.00 and gave the stock a "neutral" rating in a research note on Tuesday. TD Cowen raised their price objective on Halozyme Therapeutics from $105.00 to $130.00 and gave the company a "buy" rating in a report on Tuesday, October 13th. Wall Street Zen raised shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Stifel Nicolaus set a $130.00 target price on shares of Halozyme Therapeutics in a research report on Friday, October 16th. Finally, Wells Fargo & Company raised their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $99.64.
Read Our Latest Stock Report on HALO
Insider Activity at Halozyme Therapeutics
In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares of the company's stock, valued at $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $109.40, for a total transaction of $2,188,000.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $83,995,132. This trade represents a 2.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 125,852 shares of company stock worth $13,538,046. Company insiders own 2.50% of the company's stock.
About Halozyme Therapeutics
(
Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.
Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.
Recommended Stories
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Halozyme Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.
While Halozyme Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.